Get to know our clinical trials

Un estudio de fase 1/2 de BMS-986449 solo y en combinación con nivolumab en participantes

LEARN MORE ABOUT: SAFETY, IDENTIFY SIDE EFFECTS AND DETERMINE A DOSE OF BMS-986449 THAT CAN BE ADMINISTERED TO PATIENTS FOR THE TREATMENT OF CERTAIN TYPES OF CANCER.

Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • ESTUDIO FASE 1/2 DE BMS-986449 ADMINISTRADO EN MONOTERAPIA Y EN COMBINACIÓN CON NIVOLUMAB EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS.
  • Code EudraCT: 2023-503484-42-00
  • Protocol number: CA120-1001
  • Promoter: Bristol Myers Squibb

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.